{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreig2rw6b575vq7ppgukatt4c3iokipawrakwzrxes66gwwbt5auriy",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mnaw2zxezc42"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreib43n3bgqxe27jixeubnty4ycklvptdvdwjwn4s53y2i6urr3eepu"
    },
    "mimeType": "image/jpeg",
    "size": 187150
  },
  "path": "/news/2026-06-addition-immunotherapy-survival-benefit-trial.html",
  "publishedAt": "2026-06-01T16:00:07.000Z",
  "site": "https://medicalxpress.com",
  "textContent": "Previously, immature overall survival results of the NRG Oncology GY018 (NRG-GY018) trial suggested that the use of the immunotherapy drug pembrolizumab in combination with chemotherapy improved overall survival for patients with advanced stage or recurrent endometrial cancer when compared to chemotherapy alone. Notably, this benefit was observed in both the mismatch repair proficient (pMMR) and mismatch repair deficient (dMMR) populations.",
  "title": "Addition of immunotherapy shows survival benefit in follow-up trial for primary advanced or recurrent endometrial cancer"
}